Latest Healthcare News

Prophecy International Holdings reports a modest revenue dip and net loss in FY25, cancels its Complexica merger, and pivots to AI-driven product innovation and cost control.

BTC Health has raised $2 million through a share placement priced at a slight premium, with director Martin Kahanovitz participating and a new South African investor joining the register.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

Swift Networks reports solid FY25 results with $17.7 million revenue and launches its next-generation Swift TV platform, backed by a recent $1.6 million capital raise and pre-orders across key sectors.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

PeopleIN Group reported a challenging FY25 with revenue down 6.5% and EBITDA down 10%, yet strengthened its balance sheet through debt reduction and a strategic sale. The company is poised to capitalise on Queensland's infrastructure boom and Defence sector opportunities.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.